Vertex: Strong Sales, Stronger Pipeline

Here's our initial take on Vertex Pharmaceuticals' (VRTX 0.14%) fourth-quarter financial report.Key MetricsMetricQ4 2023Q4 2024Changevs. ExpectationsRevenue$2.52 billion$2.91 billion16%BeatEarnings per share$3.71$3.50-6%MissedTrikafta/Kaftrio revenue$2.33 billion$2.72 billion17%n/aOther product revenue$184.4 million$191.2 million4%n/aVertex reported solid fourth-quarter numbers throughout its business. While the company's earnings per share came in slightly shy of expectations, top-line revenue growth was a ...